• Incruse®▼ Ellipta® 55 micrograms (umeclidinium bromide) manufactured by GSK is a dry powder for inhalation which was launched in the UK in July 2014. UKMI has assessed this new product using the UKMI product safety tool.
  • The product is indicated for maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). It one of three Ellipta® inhalers available the UK.
    Other Ellipta® products are:
  • Relvar®▼ containing vilanterol trifenetate and fluticasone (note: two strengths are available; the 99/22 microgram strength is licensed for COPD and asthma and the 184/22 microgram strength is licensed for asthma only).
  • Anoro®▼containing vilanterol trifenatate and umeclidinium bromide

NOTE: The content of this resource has not been updated since the publication date. Some information may be out of date and links to other documents or website may not work.